Most strikingly, our results indicate that the potency of DAR B9 against Acinetobacter baumannii and P. aeruginosa is at least 8-fold higher than that of DAR A. Intrigued by these results, we profiled DAR B and B9 against the clinical CF P. aeruginosa isolates. Here, ADAR is linked to cystic fibrosis.